ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary
| Autor: | Iris Parrini, Daniella Bovelli, Luigi Tarantini, Luisa De Gennaro, Donatella Del Sindaco, Maurizio Giuseppe Abrignani, Angela Beatrice Scardovi, Irma Bisceglia, Michele Massimo Gulizia, Nicola Maurea, Francesca Macera, Donatella Radini, Giulia Russo, Andrea Di Lenarda, Alessandro Inno |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Cardiotoxicity Executive summary business.industry Cancer Disease Articles 030204 cardiovascular system & hematology medicine.disease Cardiovascular disease Cancer treatment 03 medical and health sciences Cardio-oncology 0302 clinical medicine Cardiac toxicity medicine 030212 general & internal medicine Cardio oncology Cardiology and Cardiovascular Medicine Intensive care medicine business Heart damage |
| Zdroj: | European Heart Journal Supplements : Journal of the European Society of Cardiology |
| ISSN: | 1554-2815 1520-765X |
| Popis: | Cardiovascular disease and cancer are leading causes of death. Both diseases share the same risk factors and, having the highest incidence and prevalence in the elderly, they often coexist in the same individual. Furthermore, the enhanced survival of cancer patients registered in the last decades and linked to early diagnosis and improvement of care, not infrequently exposes them to the appearance of ominous cardiovascular complications due to the deleterious effects of cancer treatment on the heart and circulatory system. The above considerations have led to the development of a new branch of clinical cardiology based on the principles of multidisciplinary collaboration between cardiologists and oncologists: Cardio-oncology, which aims to find solutions to the prevention, monitoring, diagnosis and treatment of heart damage induced by cancer care in order to pursue, in the individual patient, the best possible care for cancer while minimizing the risk of cardiac toxicity. In this consensus document we provide practical recommendations on how to assess, monitor, treat and supervise the candidate or patient treated with potentially cardiotoxic cancer therapy in order to treat cancer and protect the heart at all stages of the oncological disease. Cardiovascular diseases and cancer often share the same risk factors and can coexist in the same individual. Such possibility is amplified by the deleterious effects of cancer treatment on the heart. The above considerations have led to the development of a new branch of clinical cardiology, based on multidisciplinary collaboration between cardiologist and oncologist: the cardio-oncology. It aims to prevent, monitor, and treat heart damages induced by cancer therapies in order to achieve the most effective cancer treatment, while minimizing the risk of cardiac toxicity. In this paper, we provide practical recommendations on how to assess, monitor, treat and supervise patients treated with potential cardiotoxic cancer therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|